Últimas noticias sobre Citius Pharma (NASDAQ:CTXR) Bolsa

Citius Pharma

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Citius Pharmaceuticals, Inc. - Common Stock

Citius Pharmaceuticals Inc

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

LIPO

In the wake of Donald Trump's <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2024 presidential win</a>, Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) has jumped 10% since Wednesday to reach $0.00001944.
Trump's victory, combined with the Republican Party's return to a Senate majority, signals a potential shift in U.S. economic policy that includes corporate tax cuts, high tariffs and an aggressive stance on inflation—factors that could reshape traditional and digital asset markets alike.
What To Know: A key driver of SHIB&#8217;s surge is Trump's pro-crypto stance, marked by his vision of the U.S. as a <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40671868/trumps-bitcoin-strategic-reserve-proposal-will-chip-away-dollars-status-warns-expert-money">"Bitcoin superpower."</a> Trump's proposal to incorporate Bitcoin into a national reserve has sent ripples through the crypto space, igniting excitement among investors who see digital assets as hedges against economic uncertainty. 
Trump's anticipated policies could stoke inflationary pressures, with JPMorgan analysts projecting up to a <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41772701/trumps-historic-return-7-ways-his-second-term-could-impact-the-us-economy">2.4% rise in inflation</a> if trade tariffs are fully enacted. In such an environment, investors often look to alternative assets like cryptocurrencies as protection against the dollar's decline. 
Shiba Inu, with its low entry price and high volatility, is a popular speculative asset among retail investors seeking both growth potential and a potential hedge against macroeconomic risks.
Read Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41825733/could-micas-passport-system-open-doors-across-europe-for-crypto-exchanges">Could MiCA&#8217;s Passport System Open Doors Across Europe For Crypto Exchanges?</a>
Shiba Inu was created as an Ethereum-based alternative to Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>), branding itself as the "Dogecoin killer." Both coins share a meme-inspired appeal, drawing in retail investors with their playful branding and community-driven support.
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. <a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a> event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.

News

$DOGE

$SHIB

What's Going On With Shiba Inu (SHIB)?

Claros Mortgage Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMTG#NYSE">CMTG</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.10 by 120 percent. The company reported quarterly sales of $64.877 million which beat the analyst consensus estimate of $57.180 million by 13.46 percent. This is a 19.46 percent decrease over sales of $80.553 million the same period last year.

Earnings

Earnings Beats

CMTG

Claros Mortgage Trust Q3 2024 Adj. EPS $0.22 Beats $0.10 Estimate, Sales $64.877M Beat $57.180M Estimate

Cibus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBUS#NASDAQ">CBUS</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.90) by 106.67 percent. The company reported quarterly sales of $1.667 million which beat the analyst consensus estimate of $611.000 thousand by 172.83 percent. This is a 250.95 percent increase over sales of $475.000 thousand the same period last year.

CBUS

Cibus Q3 2024 Adj. EPS $0.06 , Sales $1.667M Beat $611.000K Estimate

President-elect Donald Trump has appointed his campaign leader, Susie Wiles, as his chief of staff. This marks the first time in US history that a woman has been appointed to this influential position.
What Happened: Wiles, a seasoned GOP operative from Florida, will assume her new role when Trump takes office in January. Trump lauded Wiles for her pivotal role in his successful 2016 and 2020 campaigns, <a href="https://thehill.com/homenews/4979786-susie-wiles-chief-of-staff/">reported</a> The Hill.
&#8220;Susie is tough, smart, innovative, and is universally admired and respected. Susie will continue to work tirelessly to Make America Great Again,&#8221; said Trump, reported The Hill.
He said, &#8220;It is a well deserved honor to have Susie as the first-ever female Chief of Staff in United States history. I have no doubt that she will make our country proud.&#8221;
Wiles, known for her low-profile approach, spearheaded Trump&#8217;s Florida operations during the 2016 campaign and later collaborated with Ron DeSantis (R) on his gubernatorial campaign. However, she left DeSantis&#8217;s team due to escalating tensions.
The chief of staff role, second only to the president in terms of influence, will see Wiles managing Trump and his team, a task that proved challenging during his first term. Trump&#8217;s initial choice for the role, Reince Priebus, was replaced after six months by John Kelly, who later became a vocal critic of Trump.
See Also: <a href="https://www.benzinga.com/news/24/11/41710411/market-analyst-who-predicted-trumps-2016-win-and-bidens-2020-victory-now-sees-former-president-retak?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Market Analyst Who Predicted Trump&#8217;s 2016 Win And Biden&#8217;s 2020 Victory, Now Sees Former President Retaking The White House With &#8216;Large Majority Of Swing States&#8217;</a>
Why It Matters: Wiles&#8217; appointment comes on the <a href="https://www.benzinga.com/news/24/11/41766547/trump-gives-victory-speech-in-florida-as-winning-pennsylvania-puts-him-at-brink-of-victory-vows-to-f">heels of Trump&#8217;s victory</a> in the 2024 presidential election. Trump&#8217;s win, which he described as &#8220;the greatest political movement of all time,&#8221; was followed by a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41807254/trump-election-raises-odds-of-roaring-2020s-scenario-veteran-wall-street-investor-s">surge in the U.S. stock market</a>, with analysts predicting a new &#8220;Roaring 2020s&#8221; scenario.
On Wednesday, after Trump won the election, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) shot up 2.5% to establish new record highs. The small-caps fund iShares Russell 2000 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) spiked 5.8%.
However, Trump also hinted at a <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">potential senior role</a> for Robert Kennedy Jr. to advance his &#8220;Make America Healthy Again&#8221; agenda, causing uncertainty in pharmaceutical stocks.
With Wiles at the helm as chief of staff, it remains to be seen how these developments will unfold and shape the course of Trump&#8217;s second term in office.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

General

Trump Appoints Susie Wiles As First Woman Chief Of Staff In US History, Calls Her Tough, Smart And Innovative

Galiano Gold (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GAU#AMEX">GAU</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $0.04 by 75 percent. This is a 40 percent increase over earnings of $0.05 per share from the same period last year. The company reported quarterly sales of $71.130 million which missed the analyst consensus estimate of $78.000 million by 8.81 percent. This is a 5.22 percent increase over sales of $67.600 million the same period last year.

Earnings Misses

Galiano Gold Q3 2024 Adj. EPS $0.07 Beats $0.04 Estimate, Sales $71.130M Miss $78.000M Estimate

HireQuest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HQI#NASDAQ">HQI</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.16 by 25 percent. The company reported quarterly sales of $9.416 million which beat the analyst consensus estimate of $8.950 million by 5.21 percent. This is a 1.56 percent increase over sales of $9.271 million the same period last year.

HireQuest Q3 2024 Adj. EPS $0.20 Beats $0.16 Estimate, Sales $9.416M Beat $8.950M Estimate

Donald Trump will return to the White House and will bring major changes to the country's tax, AI and energy policies. RBC Capital Markets analyst Deane Dray highlighted some of the companies that may benefit <a href="https://www.benzinga.com/government/24/11/41828468/trump-says-hed-replace-income-taxes-with-tariffs-the-potential-economic-fallout">from Trump's policies. </a>
Fossil Fuel/ Energy Independence: Trump's plans for energy independence would reverse many of the Biden administration's policies in order to reinvigorate the fossil fuel industry. He aims to expand the construction of pipelines, grids, ports and refineries and emphasizes utilizing domestic oil, gas and coal resources. Dray pointed to Flowserve Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) and Emerson Electric Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) as potential beneficiaries of Trump's energy policies. 
Read Next: <a href="https://www.benzinga.com/news/24/11/41781921/what-does-trumps-victory-mean-for-ev-giant-tesla-and-the-big-3-automakers">What Does Trump&#8217;s Victory Mean For EV Giant Tesla And The Big 3 Automakers?</a>
Rollback of IRA/ Reduced Clean Energy Investments: Trump has said he plans<a href="https://www.benzinga.com/news/24/07/39854007/trump-says-he-will-end-the-electric-vehicle-mandate-on-day-one-days-after-tesla-ceo-elon-musks-endor"> to eliminate</a> many vehicle emissions standards under the Environmental Protection Agency as well as many EV incentives included in the Biden administration&#8217;s Inflation Reduction Act (IRA). 
The RBC analyst again pointed to oil and gas companies as the key companies that could benefit from these potential policy adjustments, but cautioned it is too early to tell what the impacts might be for nuclear power companies. 
More Flexible/Reduced AI Regulation: RBC expects a Trump administration to be in favor of Big Tech and AI developers as he has called for a review of "unnecessary and burdensome regulations" on AI. The firm also pointed out that multi-industry data center-exposed stocks outperformed the sector by 500 basis points the day after Trump won the election. 
Dray said multi-industry companies involved in data centers that could benefit from Trump's less restrictive AI policies include nVent Electric Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVT#NYSE">NVT</a>) and Eaton Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>). 
Lower Corporate Tax Rate: Trump <a href="https://www.benzinga.com/government/24/10/41623850/trump-vs-harris-how-the-candidates-corporate-tax-proposals-stack-up">shared his plans</a> to lower the corporate tax rate to 15% for companies that make their products in the U.S. The RBC analyst sees lower corporate tax rates could lead to more reshoring from semiconductor and pharmaceutical companies and potentially more investment in the US. 
Dray pointed to Roper Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROP#NASDAQ">ROP</a>) specifically, but most publicly traded companies could benefit from lower tax rates. 
The Takeaway: "The bottom line is that early stock moves are playing out according to script, with the early stock outperformers being the electricals and oil and gas exposed names," Dray wrote. 
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/11/41774549/trumps-big-tech-policies-what-gop-victory-means-for-apple-google-microsoft">Trump&#8217;s Big Tech Policies: What GOP Victory Means For Apple, Google, Microsoft</a></li>
</ul>
Photo: Shutterstock

Government

Movers

How To Play The 'Trump Trade' For AI, Energy, Taxes: Analyst Says 5 Stocks Could Shine

Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(2.03) by 10.34 percent. The company reported quarterly sales of $1.650 million which beat the analyst consensus estimate of $1.635 million by 0.92 percent. This is a 9.19 percent decrease over sales of $1.817 million the same period last year.

AVGR

Avinger Q3 2024 GAAP EPS $(1.82) Beats $(2.03) Estimate, Sales $1.650M Beat $1.635M Estimate

Globalstar (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#AMEX">GSAT</a>) raises FY2024 sales outlook from $235.00 million-$250.00 million to $245.00 million-$250.00 million.

Guidance

GSAT

Globalstar Raises FY2024 Sales Guidance from $235.00M-$250.00M to $245.00M-$250.00M

VistaGen Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTGN#NASDAQ">VTGN</a>) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.39) by 7.69 percent. This is a 36.36 percent increase over losses of $(0.66) per share from the same period last year. The company reported quarterly sales of $183.000 thousand which missed the analyst consensus estimate of $223.333 thousand by 18.06 percent. This is a 34.10 percent decrease over sales of $277.700 thousand the same period last year.

VTGN

VistaGen Therapeutics Q2 2025 GAAP EPS $(0.42) Misses $(0.39) Estimate, Sales $183.000K Miss $223.333K Estimate

Nutex Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) reported quarterly losses of $(1.72) per share. This is a 37.6 percent decrease over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $78.795 million which beat the analyst consensus estimate of $73.225 million by 7.61 percent. This is a 25.62 percent increase over sales of $62.723 million the same period last year.

NUTX

Nutex Health Q3 2024 GAAP EPS $(1.72) Down From $(1.25) YoY, Sales $78.795M Beat $73.225M Estimate

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBR#NYSE">PBR</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.78 by 17.95 percent. The company reported quarterly sales of $23.366 billion which beat the analyst consensus estimate of $22.574 billion by 3.51 percent. This is a 8.56 percent decrease over sales of $25.552 billion the same period last year.

PBR/A

Petroleo Brasileiro S.A.- Petrobras American Depositary Shares Q3 2024 GAAP EPS $0.92 Beats $0.78 Estimate, Sales $23.366B Beat $22.574B Estimate

MannKind (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNKD#NASDAQ">MNKD</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 200 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $70.079 million which missed the analyst consensus estimate of $74.500 million by 5.93 percent. This is a 36.73 percent increase over sales of $51.253 million the same period last year.

MNKD

MannKind Q3 2024 Adj. EPS $0.06 Beats $0.03 Estimate, Sales $70.079M Miss $74.500M Estimate

Goldman Sachs BDC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSBD#NYSE">GSBD</a>) reported quarterly earnings of $0.57 per share which beat the analyst consensus estimate of $0.55 by 3.64 percent. The company reported quarterly sales of $110.413 million which missed the analyst consensus estimate of $115.264 million by 4.21 percent. This is a 8.03 percent decrease over sales of $120.056 million the same period last year.

GSBD

Goldman Sachs BDC Q3 2024 Adj. EPS $0.57 Beats $0.55 Estimate, Sales $110.413M Miss $115.264M Estimate

BanColombia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIB#NYSE">CIB</a>) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.43 by 4.2 percent. The company reported quarterly sales of $1.257 billion which missed the analyst consensus estimate of $1.573 billion by 20.10 percent. This is a 4.92 percent increase over sales of $1.198 billion the same period last year.

BanColombia Q3 2024 GAAP EPS $1.49 Beats $1.43 Estimate, Sales $1.257B Miss $1.573B Estimate

The 2028 presidential election will be held on Nov. 7, 2028, and is over 1,400 days away but that hasn't stopped sportsbooks and prediction markets from forecasting who will win the next election after Donald Trump claimed victory in the<a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election"> 2024 presidential election.</a>
2028 Election Betting Odds: While betting on U.S. elections is illegal for American sportsbooks, there are betting odds at sportsbooks around the world. Prediction markets and online stock brokerages have also<a href="https://www.benzinga.com/fintech/24/11/41783293/robinhood-reports-record-overnight-trading-volume-400-million-2024-election-contracts-traded"> launched regulated election contract options</a> in recent months.
Here is an early look at the 2028 election betting odds.
From Bookies.com, here are the current betting <a href="https://bookies.com/news/2028-us-presidential-election-odds-who-will-succeed-donald-trump">odds</a>:
<ul>
<li>J.D. Vance (Republican): +450</li>
<li>Gavin Newsom (Democrat): +575</li>
<li>Ron DeSantis (Republican): +700</li>
<li>Michelle Obama (Democrat): +950</li>
<li>Josh Shapiro (Democrat): +1,000</li>
<li>Kamala Harris (Democrat): +1,200</li>
<li>Andy Beshear (Democrat): +1,200</li>
<li>Nikki Haley (Republican): +1,200</li>
<li>Vivek Ramaswamy (Republican): +1,300</li>
<li>Wes Moore (Democrat): +1,700</li>
<li>Tom Cotton (Democrat): +1,700</li>
<li>Glenn Youngkin (Republican): +2,500</li>
<li>Aaron Rodgers (Independent): +3,000</li>
<li>Dwayne Johnson (Democrat): +3,500</li>
<li>Mark Cuban (Democrat): +3,500</li>
<li>Field (All others including Gretchen Whitmer, Marco Rubio, Ted Cruz): +2,000</li>
</ul>
Here are the current betting odds from SportsBettingDimes:
<ul>
<li>J.D. Vance (Republican): +300</li>
<li>Michelle Obama (Democrat): +500</li>
<li>Gavin Newsom (Democrat): +550</li>
<li>Ron DeSantis (Republican): +800</li>
<li>Tulsi Gabbard (Republican): +1,000</li>
<li>Hillary Clinton (Democrat): +1,400</li>
<li>Tucker Carlson (Republican): +1,400</li>
<li>Nikki Haley (Republican): +2,500</li>
<li>Oprah Winfrey (Democrat): +2,500</li>
<li>Kamala Harris (Democrat): +2,500</li>
</ul>
Bet365 does not currently list individual betting odds for who will win but has the option to bet on which party will win with Republicans favored at -150 implying a 60% chance of winning with Democrats the underdog at +120, as reported by <a href="https://www.covers.com/politics/2028-us-election-odds-republican-party-favored-nov-6-2024">Covers</a>.
Prediction market Kalshi, which is legal to U.S. bettors, also has several betting markets open for 2028 including the winning <a href="https://kalshi.com/markets/kxpresparty/party-winning-presidency">party </a>with Republicans at 49% and Democrats at 51%.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomr/republican-primary-winner">odds </a>on Kalshi for the Republican Party nominee for the 2028 election:
<ul>
<li>J.D. Vance: 57%</li>
<li>Donald Trump Jr.: 7%</li>
<li>Ron DeSantis: 6%</li>
<li>Donald Trump: 4%</li>
<li>Glenn Youngkin: 4%</li>
<li>Vivek Ramaswamy: 4%</li>
</ul>
The 22nd Amendment currently would keep Trump from serving more than two terms in the White House, but he's included in Kalshi's odds here.
Here are the betting <a href="https://kalshi.com/markets/kxpresnomd/democratic-primary-winner#kxpresnomd-28">odds </a>on Kalshi for the Democrat Party nominee for the 2028 election:
<ul>
<li>Gavin Newsom: 16%</li>
<li>Josh Shapiro: 16%</li>
<li>Gretchen Whitmer: 14%</li>
<li>Pete Buttigieg: 11%</li>
<li>Wes Moore; 9%</li>
<li>J.B. Pritzker: 9%</li>
<li>Alexandria Ocasio-Cortez: 7%</li>
<li>Michelle Obama: 6%</li>
<li>Kamala Harris: 2%</li>
</ul>
Polymarket, which <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41694948/trump-polymarket-whale-has-30m-bet-on-former-president-winning-2024-election-my-intent-is-">had many prediction markets</a> on the 2024 election does not currently offer 2028 markets. The decentralized platform allows users to deposit funds using USDC (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDC</a>) via the Polygon (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/matic/usd">MATIC</a>) network or directly from a crypto account with Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>). The platform will be closely watched in the coming months to see who takes the early lead in 2028 election betting.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent110724">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: Polymarket saw over $3 billion bet on the 2024 election winner market with various other markets attracting high betting volume.
Kalshi had over $100 million wagered on<a href="https://www.benzinga.com/general/politics/24/11/41701133/more-than-100m-wagered-on-presidential-race-on-kalshi"> the 2024 election outcome.</a>
Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) had over 400 million contracts traded during the 2024 election.
While betting on the outcomes of U.S. elections is not legal at sportsbooks for America, people around the world were placing wagers along with prediction markets and brokerages trading contracts to take advantage of strong user demand.
By the time the 2028 election rolls around there could be even more betting options and election betting<a href="https://www.benzinga.com/general/sports-betting/23/05/32244769/exclusive-draftkings-benefits-from-non-nfl-sports-growth-eyes-horse-racing-and-election-be"> could be legal at sportsbooks. </a>While things could look different in the coming years, the betting odds above will likely look different as candidates decide to run or withdraw their names from consideration.
It's likely not a surprise that Vance is the early betting favorite as the future vice president won the 2024 election ticket with Trump and would be the frontrunner for the Republican Party. The big question is if Harris will run for president again and if not her, who will be the frontrunner for the Democratic Party.
Harris <a href="https://www.benzinga.com/general/sports-betting/24/10/41347270/trump-vs-harris-2024-election-polls-sportsbooks-betting-odds-show-different-winners-for-20">was the favorite </a>at +350 for the 2024 election after Joe Biden won the 2020 election as the current president originally said he would not run a second term. Biden and Trump trailed Harris in January 2021 betting odds to win the 2024 race at +400 and +650, respectively.
With Biden running again, the odds favored Biden, Trump and DeSantis, who ran in the Republican primary, for many months. With Biden dropping out, sportsbooks favored Harris before the odds shifted to Trump in the months leading up to the 2024 election.
While an Independent candidate has never won the election, the listing of Rodgers, who is the quarterback of the NFL's New York Jets, has captured some attention.
"I can't believe we live in a world where my QB has better odds to win the 2028 presidential election than my team does to win the Super Bowl," X user @blakenyjets <a href="https://x.com/blakenyjets/status/1854291783754363114">said</a>.
The New York Jets, who started the season as one of the favorites to win Super Bowl LIX, are currently 3-6 and the odds at DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) of a Super Bowl victory are +2,500 today.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41819799/polymarket-ceo-on-election-night-it-looked-like-a-done-deal-on-platform-but-just-watching-">Polymarket CEO On Election Night: &#8216;It Looked Like A Done Deal&#8217; On Platform, But Just Watching TV &#8216;You Would Think It&#8217;s Neck And Neck&#8217;</a></li>
</ul>
Photo: Meeboonstudio via Shutterstock

Sports Betting

$ETH

$MATIC

$USDC

DKNG

HOOD

USDC

2028 Election Betting Odds: Where Do J.D. Vance, Michelle Obama, Mark Cuban, Ron DeSantis, Kamala Harris Rank?

SANUWAVE Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SNWV#OTC">SNWV</a>) reported quarterly losses of $(6.49) per share. This is a 42.31 percent increase over losses of $(11.25) per share from the same period last year. The company reported $9.36 million in sales this quarter. This is a 88.98 percent increase over sales of $4.95 million the same period last year.

SNWV

SANUWAVE Health Q3 EPS $(6.49) Up From $(9.95) YoY, Sales $9.36M Up From $4.95M YoY

Freehold Royalties (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FRHLF#OTC">FRHLF</a>) reported quarterly earnings of $0.12 per share. This is a 42.86 percent decrease over earnings of $0.21 per share from the same period last year. The company reported $54.17 million in sales this quarter. This is a 13.73 percent decrease over sales of $62.79 million the same period last year.

FRHLF

Freehold Royalties Q3 EPS $0.12 Down From $0.21 YoY, Sales $54.17M Down From $62.79M YoY

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Citius Pharmaceuticals (CTXR – Research Report) and ...

Analysts Are Bullish on Top Healthcare Stocks: Citius Pharmaceuticals (CTXR), Actinium Pharmaceuticals (ATNM)

H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on Citius Pharmaceuticals (CTXR – Research Report) today and set a price target o...

Buy Rating Reaffirmed for Citius Pharmaceuticals Amid Strong Clinical Trial Results and Growth Prospects

There are few sectors that can offer investors massive returns – but biotech comes to mind as one. These companies are typically involved in the ph...

2 Biotech Stocks With Big FDA Decisions Approaching – Here's What Analysts Expect

Citius wins FDA nod for Lymphir in cutaneous T-cell lymphoma

Catalyst Watch: Eyes on Walmart earnings, the July CPI print, and 13F filings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Citius Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctxr-stock-quote/">CTXR</a>) just reported results for the third quarter of 2024.<ul><li>Citius Pharma reported earnings per share of -6 cents. This met the analyst estimate for EPS of -6 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ctxr-stock-earnings-citius-pharma-for-q3-of-2024/">CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTXR Stock Earnings: Citius Pharma Meets EPS for Q3 2024

Citius Pharmaceuticals GAAP EPS of -$0.06 misses by $0.01

Analyst Michael Okunewitch of Maxim Group reiterated a Buy rating on Citius Pharmaceuticals (CTXR – Research Report), retaining the price target of...

Lymphir: A Promising Contender in the r/r CTCL Market with Strong Commercial Prospects

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Citius Pharmaceuticals (CTXR – Research Report), wit...

Buy Rating Affirmed for Citius Pharmaceuticals Amid Strategic Oncology Spinout and Promising Lead Product Data

Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more

AAPL

AMAT

AMZN

ASND

ATNM

ATXS

AYRO

BABA

BDTX

BIDU

BILI

BTBT

CARA

CATO

CHGG

CHUY

CIFR

CMPX

COIN

COTY

CRUS

CRWD

CSCO

CSIQ

CTXR

DAVE

DESP

ENVA

ESTC

FIVE

FLUT

FORD

FUTU

FWRD

GGAL

GOLD

GOOG

GOOGL

GTHX

IDXX

ILMN

IMMR

INTC

INTU

ISPO

IVCA

JKHY

KEYS

LUMN

MBRX

MMAT

MNDY

MSCI

MSFT

NNDM

NNOX

NTES

NVDA

OKLO

ONON

PANW

PGNY

PINS

PTON

ROST

SAVE

SEEL

SMCI

SNAP

SNOW

SNPS

SPRY

SSNLF

SXTP

TSLA

URBN

VIPS

WDAY

WKHS

WOLF

WULF

XPEV

Screenshot 2024-08-06 at 7.17.40 PM

Biotech

TENK

Citius Pharmaceuticals To Receive 65 Million Shares Of TenX Keane For Merger Of Citius Oncology

Screenshot 2024-07-29 at 8.39.42 PM

From fighting cancer to treating bloodstream infections, Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is busy trying to solve some of the world&#39;s ills. That&#39;s picking up steam with two of its lead products close to commercialization. 

Citius Pharmaceuticals Nears Market Breakthrough With Two Leading Products

Screenshot 2024-07-24 at 5.43.01 PM

Interview

This Pharma Company Is Preparing To Launch Its Lead Candidate

Screenshot 2024-04-17 at 5.34.28 PM

Citius Pharmaceuticals (NASDAQ: CTXR) Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment

Press Releases

Citius Pharmaceuticals Announces TenX Keane Shareholder Approval of Merger with Citius Oncology, Inc.

TenX Keane Acquisition Shareholders Approve Previously Announced Merger to Form Citius Oncology, Inc., a Publicly Listed Subsidiary of Citius Pharmaceuticals

Citius Pharmaceuticals Receives FDA Approval for LYMPHIR™ (denileukin diftitox-cxdl) Immunotherapy for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma

TenX Keane Acquisition Addresses Trading Halt, Continues Towards Closing of Business Combination, and Provides Market Update

Small Cap

Citius Pharmaceuticals to Host Investor Call to Discuss Recent and Upcoming Developments

Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2024 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology

Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Comments

Citius Pharma

Noticias

Últimas noticias sobre Citius Pharma (NASDAQ:CTXR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL